The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndrome

Clinical and Diagnostic Laboratory Immunology

Volumn 4, Issue 2, 1997, Pages 113-116

  Myc, Andrzej ^a,e   Buck, Jochen ^b   Gonin, Joyce ^a   Reynolds, Brian ^c   Hammerling, Ulrich ^d   Emanuel, David ^a  

^a RILEY HOSPITAL FOR CHILDREN   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ALMA COLLEGE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY;

ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; INFLAMMATION; PRIORITY JOURNAL; SEPTIC SHOCK;

EID: 0030895403     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/cdli.4.2.113-116.1997     Document Type: Article

References (27)

1. Abraham, E., R. Wunderink, H. Silverman, T. M. Perl, S. Nasraway, H. Levy, R. Bone, R. P. Wenzel, R. Balk, R. Alfred, et al. 1995. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha Mab Sepsis Study Group. JAMA 273:934-941.
2. Beal, A. L., and F. B. Cerra. 1994. Multiple organ failure syndrome in the 1990s. JAMA 271:226-233.
3. Bone, R. C. 1995. Sepsis, sepsis syndrome, and the systemic inflammatory response syndrome (SIRS). JAMA 273:155-156.
4. Bone, R. C., R. A. Balk, A. M. Fein, T. M. Perl, R. P. Wenzel, H. D. Reines, R. W. Quenzer, T. J. Iberti, N. MacIntyre, and R. M. Schein. 1995. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit. Care Med. 23:994-1006.
5. Bone, R. C., R. A. Balk, F. C. Cerra, et al. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101:1644-1655.
6. Calvano, S. E., W. A. Thompson, M. N. Marra, S. M. Coyle, H. F. de Riesthal, R. K. Trousdale, Ph. S. Barie, R. W. Scott, L. L. Moldawer, and S. F. Lowry. 1994. Changes in polymorphonuclear leukocyte surface and plasma bactericidal/permeability-increasing protein and plasma lipopolysaccharide binding protein during endotoxemia or sepsis. Arch. Surg. 129:220-226.
7. Centers for Disease Control. 1990. Increase in national discharge survey rates for septicemia - United States, 1979-1987. Morbid. Mortal. Weekly Rep. 39:31-34.
8. Cross, A. S., H. Sidberry, and J. C. Sadoff. 1989. The human antibody response during natural bacteremic infection with gram-negative bacilli against lipopolysaccharide core determinants. J. Infect. Dis. 160:225-226.
9. Fisher, C. J., Jr., J. F. Dhainaut, S. M. Opal, J. P. Pribble, R. A. Balk, G. J. Slotman, T. J. Iberti, E. C. Rackow, M. J. Shapiro, R. L. Greenman, et al. 1994. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIl-lra Sepsis Syndrome Study Group. JAMA 271:1836-1843.
10. Gallay, P., C. Barras, P. Tobias, et al. 1994. Lipopolysaccharide (LPS)-binding protein in human serum determines the tumor necrosis factor response of monocytes to LPS. J. Infect. Dis. 170:1319-1322.
11. Greenman, R. L., R. M. Schein, M. A. Martin, R. P. Wenzel, N. R. MacIntyre, G. Emmanuel, H. Chmel, R. B. Kohler, M. McCarthy, J. Plouffe, et al. 1991. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 266:1097-1102.
12. Grube, B. J., C. G. Cochane, R. D. Ye, C. E. Green, M. E. McPhail, R. J. Ulevitch, and P. S. Tobias. 1994. Lipopolysaccharide binding protein expression in primary human hepatocytes and Hep G2 hepatoma cells. J. Biol. Chem. 269:8477-8482.
13. Heumann, D., P. Gallay, D. Le Roy, R. Landmann, and M. P. Glauser. 1994. Radioimmunoassay versus flow cytometric assay to quantify LPS-binding protein (LBP) concentrations in human plasma. J. Immunol. Methods 171: 169-176.
14. Leturcq, D., P. VanHook, R. Smith, P. S. Tobias, R. J. Ulevitch, and A. Moriarty. 1992. Generation of monoclonal antibodies to human LBP and their use in the detection of LBP protein in serum. J. Cell. Biochem. 16C(Suppl.):161.
15. Michie, H. R., K. R. Manogue, D. R. Spriggs, A. Revhaug, S. I. Dwyer, C. A. Dinarello, A. Cerami, S. M. Wolff, and D. W. Wilmore. 1988. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 318:1481-1486.
16. Opal, S. M., J. E. Palardy, M. N. Marra, C. J. Fisher, B. M. McKelligon, and R. W. Scott. 1994. Relative concentrations of endotoxin-binding proteins in body fluids during infection. Lancet 344:429-431.
17. Parrillo, J. E. 1991. Management of septic shock: present and future. Ann. Intern. Med. 115:491-493.
18. Parrillo, J. E., M. M. Parker, C. Natanson, et al. 1990. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy. Ann. Intern. Med. 113:227-242.
19. Ramadori, G., K. H. Meyer zum Buschenfelde, P. S. Tobias, J. C. Mathinson, and R. J. Ulevitch. 1990. Biosynthesis of lipopolysaccharide-binding protein in rabbit hepatocytes. Pathobiology 58:89-94.
20. Rangel-Frausto, M. S., D. Pittet, M. Costigan, T. Hwang, C. S. Davis, and R. P. Wenzel. 1995. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273:117-123.
21. Schumann, R. R., S. R. Leong, G. W. Flaggs, P. W. Gary, S. D. Wright, J. C. Mathison, P. S. Tobias, and R. J. Ulevitch. 1990. Structure and function of lipopolysaccharide binding protein. Science 249:1429-1431.
22. Theofan, G., A. H. Horwitz, R. E. Williams, P. S. Liu, I. Chan, C. Birr, S. F. Carroll, K. Meszaros, J. B. Parent, H. Kasler, S. Aberle, P. W. Trown, and H. Gazzano-Santoro. 1994. An amino-terminal fragment of human lipopolysaccharide-binding protein retains lipid A binding but not CD14-stimulatory activity. J. Immunol. 152:3623-3629.
23. Tobias, P. S., K. Soldau, and R. J. Uleviteh. 1989. Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein, J. Biol. Chem. 264:10867-10871.
24. Tobias, P. S., K. Soldau, and R. J. Ulevitch. 1986. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J. Exp. Med. 164: 777-793.
25. Tobias, P. S., and R. J. Ulevitch. 1983. Control of lipopolysaccharide-high density lipoprotein binding by acute phase protein(s). J. Immunol. 131:1913-1916.
26. Wright, S. D., R. A. Ramos, P. S. Tobias, R. J. Ulevitch, and J. C. Mathison. 1990. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431-1433.
27. Ziegler, E. J., C. J. Fisher, Jr., C. L. Sprung, R. C. Straube, J. C. Sadoff, G. E. Foulke, C. H. Wortel, M. P. Fink, R. P. Dellinger, N. N. Teng, I. E. Allen, H. J. Berger, G. L. Knatterud, et al. 1991. Treatment of gram-negative bacteremia and septic shock with randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N. Engl. J. Med. 324:429-436.